Alluvi Tirzepatide (Mounjaro) 40mg (4 x 10mg Doses)
£100.00
Alluvi Tirzepatide (Mounjaro) 40mg — dual-agonist research peptide targeting GLP-1 and GIP receptors. 40mg total active compound supplied as 4 doses of 10mg. 99.85% purity, Janoshik Analytical tested, batch COA available. Cold-chain UK delivery. For laboratory and scientific research use only.
50 in stock
Description
Alluvi Tirzepatide is a research-grade dual-agonist peptide formulation examined for metabolic pathway interaction and endocrine signalling behaviour in controlled laboratory settings. It acts on GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors simultaneously — a mechanism that distinguishes it from single-pathway compounds such as semaglutide.
Alluvi Healthcare provides this compound in a precisely measured, highly purified pre-filled format designed for structured laboratory assessment.
What is Alluvi Tirzepatide (Mounjaro)?
Most older compounds in this class activate one receptor pathway. Tirzepatide activates two — GLP-1 and GIP — at the same time. Because it engages both receptors, research interest focuses on four distinct areas of metabolic physiology:
- Appetite signalling: Effects on central pathways linked to hunger and fullness are reported in published literature.
- Gastric emptying: Slower movement of food from the stomach is reported, particularly in early phases, which affects the timing of nutrient absorption.
- Glucose-dependent insulin secretion: Insulin release from pancreatic beta cells is reported when glucose is elevated. The response is glucose-dependent, so the intrinsic hypoglycaemia risk reported in the literature is lower than for some other glucose-lowering compounds.
- Glucagon regulation: Reduced fasting and post-meal glucagon concentrations are reported in type 2 diabetes studies, limiting glucose release from the liver.
These are pharmacological observations from published research. They are not treatment outcomes, and this material is not supplied for human use.
Product Specifications
How Does Tirzepatide Work? (Dual-Target Mechanism)
Tirzepatide is built to bind to and activate both natural incretin hormone receptors simultaneously. This dual-target mechanism engages several metabolic checkpoints studied in research models:
Central Appetite Regulation and Satiety
The hypothalamus controls hunger signals. Tirzepatide affects brain pathways linked to hunger and fullness, with appetite reduction and satisfaction with smaller food intake reported in research models.
Slower Digestion and Extended Fullness
Tirzepatide slows gastric emptying — food leaves the stomach more slowly, especially in early phases. This affects how nutrients are absorbed and changes the post-meal glucose response.
Glucose-Dependent Insulin Regulation
Tirzepatide prompts pancreatic beta cells to release insulin when blood glucose is high. Because the response is glucose-dependent, the intrinsic hypoglycaemia risk is lower than for some other glucose-lowering medicines — though this risk rises when combined with insulin or sulfonylureas.
Glucagon Regulation and Liver Glucose Production
Tirzepatide can reduce elevated glucagon levels in type 2 diabetes models, limiting unnecessary glucose release from the liver. Published studies also report improvements in insulin sensitivity during tirzepatide treatment.
What Published Trials Report
Tirzepatide has been evaluated in the SURPASS trials (type 2 diabetes) and SURMOUNT trials (weight management). The figures below are trial findings reported in the literature — not a statement about this product.
43% post-meal
higher doses vs baseline
of adults in clinical studies
over 40 weeks at 10mg vs single-agonist comparator
The Alluvi Healthcare Standard
When procuring research peptides, quality control and structural integrity are paramount. Alluvi Healthcare focuses on:
- Lab Tested for Purity: Independent Janoshik Analytical testing — HPLC and mass spectrometry — per batch. Live verification pages with task numbers, checkable directly with the lab.
- High-Quality Ingredients: Premium raw materials selected for purity, quality, and consistency. Manufacturing and handling standards are designed to maintain product integrity.
- Cold Chain Delivered: Cold-pack dispatch with insulated packaging. Refrigerated storage at 2°C to 8°C maintained throughout transportation.
- Batch Traceability: Batch reference links your pen to the published certificate. Measured content published — 40.05mg verified, not assumed from the label.
- Trusted by Professionals: A quality-focused approach for researchers and professionals requiring dependable peptide specifications, consistent standards, and reliable service.
Storage and Handling
Tirzepatide is temperature sensitive. Handling conditions determine whether the material behaves as the certificate describes.
- Refrigerate at 2°C to 8°C on arrival. Protect from light. Never freeze.
- Keep the pen sealed until use. Check tamper-evident holographic and UV watermark seals on receipt.
- Match the batch number (TR786PAOS) to the COA and check the expiry. Refrigerate immediately.
- Report damaged packaging, label discrepancies, or suspected temperature excursions to the support team.
- Purity is not sterility. A high purity result does not establish sterility or suitability for any route of administration.
Important Research Disclaimer
Strictly for Laboratory and Scientific Research Use Only.
Alluvi Tirzepatide is not intended for human consumption, veterinary use, self-administration, clinical use, treatment, diagnosis, prevention, cosmetic use, supplement use, body composition use, wellness use, weight-loss use, or any form of personal use.
We do not provide dosing guidance, preparation instructions, administration guidance, injection advice, clinical-use guidance, or personal-use support. Customers must ensure that all products are handled responsibly within appropriate laboratory and scientific research environments.
Frequently Asked Questions
What purity level is the peptide and how is it verified?
99.85% on batch TR786PAOS, tested by Janoshik Analytical using HPLC and mass spectrometry. The certificate is published on the verification page with task number 147174, checkable directly with the lab. We publish measured content — 40.05mg — not a pass/fail.
How do I read the COA?
Each certificate shows peptide identity, purity by the stated method, assay content in mg/mL, the batch reference, and the raw chromatogram. Match the batch number on your pen to the certificate before you use the material.
How should I store it?
Refrigerate at 2°C to 8°C on arrival. Protect from light. Never freeze. The Alluvi RT·56 study reports 56 days at ambient temperature with purity, concentration, and pH retained. Published label data for tirzepatide covers 21 days at up to 30°C. Long-term storage requires refrigeration.
Can I check the COA before I buy?
Yes. The Janoshik verification page for batch TR786PAOS is linked on this product page. You can check the results for yourself before placing an order.
What is the biological half-life of Tirzepatide in testing models?
Tirzepatide has an extended elimination half-life of approximately 5 days. This extended duration allows the compound to maintain steady-state plasma concentrations, making it relevant for once-weekly administration schedules studied in long-term metabolic and laboratory research.
How does Tirzepatide achieve its prolonged duration of action?
Tirzepatide is built with a C20 fatty diacid attached to its sequence. This allows the compound to bind closely to albumin, a protein in the bloodstream, which prevents rapid enzymatic breakdown and greatly extends its active half-life.
What happens if the cold chain is temporarily broken during laboratory handling?
Long-term storage requires strict refrigeration, but published label data reports that tirzepatide can be stored unrefrigerated at temperatures up to 30°C (86°F) for a maximum of 21 days. The Alluvi RT·56 study reports 56 days at ambient temperature with purity, concentration, and pH retained (Janoshik Analytical). These are two separate figures and should not be merged.
Does Tirzepatide influence glucagon levels differently than single-agonists?
Yes. Tirzepatide actively reduces both fasting and post-meal glucagon concentrations. In pharmacological studies, subjects using higher doses saw a 28% reduction in fasting glucagon levels and a 43% reduction in post-meal glucagon levels compared to baseline. Single-pathway drugs do not replicate this combined effect.
Does Tirzepatide have any notable cardiovascular or heart rate effects?
Clinical data indicates that Tirzepatide can cause small increases in resting heart rate. In placebo-controlled trials, subjects had a mean increase of 2 to 4 beats per minute, with some testing models reporting temporary episodes of sinus tachycardia (a fast but regular heartbeat).
Are dosage adjustments required for subjects with renal or hepatic impairment?
Pharmacokinetic analyses show that Tirzepatide’s performance is highly consistent. Its efficacy and clearance rates are not clinically affected by intrinsic factors such as age, gender, race, or baseline body weight. No dosage adjustments are reported as required for subjects with varying degrees of kidney (renal) or liver (hepatic) impairment.
What is the difference between peptide purity and concentration?
Purity is how much of the sample is the intended peptide compared with other detected components. Concentration is how much substance is in a set amount or volume of formulation. These are two different measurements — you cannot reliably calculate one from the other.
Are these peptides for human use?
No. All products are reference materials supplied for in-vitro and laboratory research only. They are not for human or veterinary use, consumption, or any therapeutic, diagnostic, or cosmetic application.
Related products
*For research purposes only. Store in a refrigerator (2°C to 8°C). For subcutaneous injection only. Read package leaflet before use.
